MPLTHealthcare · BiotechnologyThe 15 Wall Street analysts covering MapLight Therapeutics, Inc. hold a median 12-month price target of $25 — +206.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores MapLight Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (64): Analysts have, on balance, been raising their forecasts.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MPLT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +206.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Oct 2026 | Guggenheim | Initiates | Neutral | — |
| 31 Aug 2026 | Needham | Maintains | Buy | — |
| 31 Aug 2026 | Needham | Maintains | Buy | $45 → $43 |
| 10 Aug 2026 | UBS | Downgrade | Neutral | $52 → $13 |
| 10 Aug 2026 | UBS | Downgrade | Neutral | — |
| 28 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 July 2026 | Canaccord Genuity | Maintains | Buy | $43 → $24 |
| 28 July 2026 | HC Wainwright & Co. | Maintains | Buy | $45 → $26 |
| 28 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 July 2026 | Morgan Stanley | Downgrade | Equal-Weight | $34 → $21 |
| 28 July 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 25 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 24 July 2026 | Canaccord Genuity | Maintains | Buy | $35 → $43 |
| 21 July 2026 | BMO Capital | Initiates | Outperform | $46 |
| 21 July 2026 | BMO Capital | Initiates | Outperform | — |
| 21 July 2026 | UBS | Maintains | Buy | — |
| 21 July 2026 | UBS | Maintains | Buy | $48 → $52 |
| 10 July 2026 | Needham | Maintains | Buy | $42 → $45 |
| 10 July 2026 | Needham | Maintains | Buy | — |
| 25 June 2026 | Raymond James | Initiates | Strong Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MPLT appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 67% of US stocks
Cheaper than 65% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MapLight Therapeutics, Inc. has a market value of $457.9M and an enterprise value of $79.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$229.8M.
Diluted earnings per share, trailing twelve months: $−5.84.
Free cash flow in the twelve months to 30 June 2026: −$175.1M.
Trailing P/E: −0.5×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MapLight Therapeutics, Inc. employs 133 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MapLight Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks says MapLight Therapeutics (MPLT) has fallen 29.2% in four weeks and may be oversold. It also cites analysts’ upward earnings-estimate revisions as a possible signal of a trend reversal.
Why it matters — MPLT watchers may note the combination of recent selling pressure, an oversold technical reading, and upward estimate revisions.
Zacks reports that MPLT has become technically oversold after a 34.8% decline over four weeks. The excerpt also cites analysts revising earnings estimates higher and describes a potential near-term trend reversal.
Why it matters — MPLT watchers may note the reported oversold condition and upward earnings estimate revisions as factors highlighted in the article.
MapLight Therapeutics said co-founder and Scientific Advisory Board member Karl Deisseroth received the 2026 Nobel Prize in Physiology or Medicine. The award recognizes foundational discoveries in optogenetics and circuit mapping.
Why it matters — The company says these discoveries helped inspire its circuit-based approach to drug discovery.
MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced that members of its management team will participate in an upcoming investor conference. The company released this announcement from San Francisco and Boston on September 9, 2026.
Why it matters — A MPLT watcher would care because management's participation in an investor conference offers investors an opportunity to hear directly from company leadership.
MapLight Therapeutics reported Q2 2026 financial results and a business update, highlighting positive Phase 2 ZEPHYR data for ML-007C-MA in schizophrenia supporting advancement to a Phase 3 trial, ongoing enrollment in the Phase 2 VISTA trial for ADP, and IRIS results for ML-004 in autism spectrum disorder. The company ended the quarter with $351.3 million in cash, which, along with a $150 million private placement, is expected to fund operations through 2028.
Why it matters — MapLight watchers would care because the positive Phase 2 ZEPHYR results and extended cash runway through 2028 position the company to advance its lead program ML-007C-MA through anticipated readouts for both VISTA and ZEPHYR-2.
The 15 Wall Street analysts covering MapLight Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $13 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering MapLight Therapeutics, Inc., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MapLight Therapeutics, Inc. 13 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Oct 2026, MapLight Therapeutics, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (64 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +206.4% from the last close, and Ticker Nerd's factor model ranks MapLight Therapeutics, Inc. 13 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MapLight Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MPLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $43 over the next 12 months.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders.
The most recent item we track (Zacks Investment Research, 16 Oct 2026): "Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)". Zacks says MapLight Therapeutics (MPLT) has fallen 29.2% in four weeks and may be oversold. It also cites analysts’ upward earnings-estimate revisions as a possible signal of a trend reversal.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s current pipeline centers on brain and neuroscience programs aimed at conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease motor symptoms, and other neuropsychiatric disorders. Its lead candidate, ML-007C-MA, is being developed as an oral fixed-dose combination therapy, while additional product candidates include ML-004, ML-021, ML-055, and ML-009. MapLight Therapeutics also uses a discovery platform designed to identify neural circuits linked to disease and guide therapeutic modulation. The company is based in Redwood City, California, and focuses on translating circuit-based neuroscience into targeted medicines for patients with serious brain disorders.
CEO Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. · 133 employees · United States · https://www.maplightrx.com
